We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Vertex Pharmaceuticals (VRTX - Free Report) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8% gain over the past four weeks.
Last week, the company announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate-to-severe acute pain. The drug will be marketed by the name of Journavx. Following the nod, Journavx became the first and only non-opioid oral pain signal inhibitor and the first new class of pain medicine to be approved by the FDA in more than 20 years. This might have driven the recent share price rally.
This drugmaker is expected to post quarterly earnings of $4 per share in its upcoming report, which represents a year-over-year change of -4.8%. Revenues are expected to be $2.77 billion, up 10.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Vertex, the consensus EPS estimate for the quarter has been revised 2% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on VRTX going forward to see if this recent jump can turn into more strength down the road.
Vertex is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Foghorn Therapeutics Inc. (FHTX - Free Report) , finished the last trading session 3.5% lower at $4.19. FHTX has returned -5.5% over the past month.
For Foghorn Therapeutics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.27. This represents a change of +52.6% from what the company reported a year ago. Foghorn Therapeutics currently has a Zacks Rank of #2 (Buy).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?
Vertex Pharmaceuticals (VRTX - Free Report) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8% gain over the past four weeks.
Last week, the company announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate-to-severe acute pain. The drug will be marketed by the name of Journavx. Following the nod, Journavx became the first and only non-opioid oral pain signal inhibitor and the first new class of pain medicine to be approved by the FDA in more than 20 years. This might have driven the recent share price rally.
This drugmaker is expected to post quarterly earnings of $4 per share in its upcoming report, which represents a year-over-year change of -4.8%. Revenues are expected to be $2.77 billion, up 10.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Vertex, the consensus EPS estimate for the quarter has been revised 2% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on VRTX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Vertex is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Foghorn Therapeutics Inc. (FHTX - Free Report) , finished the last trading session 3.5% lower at $4.19. FHTX has returned -5.5% over the past month.
For Foghorn Therapeutics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.27. This represents a change of +52.6% from what the company reported a year ago. Foghorn Therapeutics currently has a Zacks Rank of #2 (Buy).